CA2168066A1 - Traitement de l'hypertension et de l'insuffisance cardiaque globale - Google Patents

Traitement de l'hypertension et de l'insuffisance cardiaque globale

Info

Publication number
CA2168066A1
CA2168066A1 CA002168066A CA2168066A CA2168066A1 CA 2168066 A1 CA2168066 A1 CA 2168066A1 CA 002168066 A CA002168066 A CA 002168066A CA 2168066 A CA2168066 A CA 2168066A CA 2168066 A1 CA2168066 A1 CA 2168066A1
Authority
CA
Canada
Prior art keywords
inhibitor
hydrogen
carbons
pharmaceutically acceptable
neutral endopeptidase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002168066A
Other languages
English (en)
Inventor
James R. Powell
Andrea Ann Seymour
Nick C. Trippodo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2168066A1 publication Critical patent/CA2168066A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002168066A 1995-02-08 1996-01-25 Traitement de l'hypertension et de l'insuffisance cardiaque globale Abandoned CA2168066A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38636695A 1995-02-08 1995-02-08
US386,366 1995-02-08

Publications (1)

Publication Number Publication Date
CA2168066A1 true CA2168066A1 (fr) 1996-08-09

Family

ID=23525298

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002168066A Abandoned CA2168066A1 (fr) 1995-02-08 1996-01-25 Traitement de l'hypertension et de l'insuffisance cardiaque globale

Country Status (4)

Country Link
EP (1) EP0726072A3 (fr)
JP (1) JPH08245385A (fr)
AU (1) AU4339896A (fr)
CA (1) CA2168066A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770640B1 (en) 1998-12-31 2004-08-03 Aventis Pharmaceuticals Inc. 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
EP1750862B1 (fr) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
WO2007045663A2 (fr) * 2005-10-19 2007-04-26 Novartis Ag Combinaison de composes organiques
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2200975A1 (fr) 2007-09-07 2010-06-30 Theravance, Inc. Agents antihypertensifs a double action
CA2705921A1 (fr) 2007-12-11 2009-06-18 Theravance, Inc. Derives de benzimidazole a double effet et leur utilisation en tant qu'antihypertenseurs
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
JP2011529072A (ja) 2008-07-24 2011-12-01 セラヴァンス， インコーポレーテッド 二重作用血圧降下薬
EP2451782B1 (fr) 2009-07-07 2016-11-09 Theravance Biopharma R&D IP, LLC Agent antihypertenseurs pyrazoles à double action
WO2011011232A1 (fr) 2009-07-22 2011-01-27 Theravance, Inc. Agents antihypertenseurs à double action à base d'oxazole
EP2526095A1 (fr) 2010-01-19 2012-11-28 Theravance, Inc. Agents antihypertenseurs de thiophène, pyrrole, thiazole et furane à double action
EA202090398A1 (ru) 2017-07-28 2020-05-15 Синтон Б.В. Фармацевтическая композиция, включающая сакубитрил и валсартан
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0566157A1 (fr) * 1986-06-20 1993-10-20 Schering Corporation Inhibiteurs de la métallo-Endopeptidase neutre dans le traitement de l'hypertension
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
EP0565634B1 (fr) * 1990-12-14 1999-03-17 Smithkline Beecham Corporation Compositions de blocage de recepteur de l'angiotensine ii
EP0498361A3 (en) * 1991-02-06 1992-09-02 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
EP0629408A1 (fr) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination d'inhibiteurs ACE et d'antagonistes AII

Also Published As

Publication number Publication date
EP0726072A3 (fr) 1997-12-17
EP0726072A2 (fr) 1996-08-14
AU4339896A (en) 1996-08-15
JPH08245385A (ja) 1996-09-24

Similar Documents

Publication Publication Date Title
CA2168066A1 (fr) Traitement de l'hypertension et de l'insuffisance cardiaque globale
Mimran et al. Effect of captopril on renal vascular tone in patients with essential hypertension
JP2008019273A (ja) 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
HUE027280T2 (en) Angiotensin II Receptor Antagonists to Treat High Blood Pressure in Cats
Ruan et al. Calcium entry and mobilization signaling pathways in ANG II-induced renal vasoconstriction in vivo
CN115297862A (zh) 包含达拉菲尼、erk抑制剂和shp2抑制剂的三重药物组合
Brown et al. The physiological and pharmacological role of presynaptic alpha‐and beta‐adrenoceptors in man.
CA2132544C (fr) Antagonistes d'angiotensine ii utiles contre les troubles lies a une vitesse alteree de l'influx nerveux, particulierement dans le cas de la neuropathie diabetique
DE69333362T2 (de) Verwendung von angiotensin antagonisten (at1) zur verminderung des erkrankungs- und todesfallrisikos nach myokardinfarkt
EP0561977B1 (fr) Utilisation d'antagonistes du recepteur de l'angiotensine ii dans le traitement d'accidents hemorragiques
US20040229901A1 (en) Method of treatment of disease using an adenosine A1 receptor antagonist
US4469690A (en) Synergistic compositions of renal dopaminergic agent and β-blocker
Rego et al. Mechanism of cyclosporin potentiation of vasoconstriction of the isolated rat mesenteric arterial bed: role of extracellular calcium.
EP0660713B1 (fr) Utilisation d'agents antagonistes de l'angiotensine ii dans le traitement de l'hypertrophie ventriculaire gauche
JP2009102399A (ja) 利尿機能および腎機能を回復するためのアデノシンａ１レセプターアンタゴニスト含有組成物および方法
Hoffman et al. Independent receptors for pressor and drinking responses to central injections of angiotensin II and carbachol
Jones Injections of phentolamine into the anterior hypothalamus-preoptic area of rats blocks both pressor and drinking responses produced by central administration of angiotensin II
KR20200026975A (ko) 고양이에서 전신 질환의 예방 또는 치료를 위한 안지오텐신 ii 수용체 길항제
Rutter et al. Sympathoadrenal mechanisms in cardiovascular responses to naloxone after hemorrhage
Moreau et al. Alteration of prejunctional α2-adrenergic autoinhibition in DOCA-salt hypertension
WO2011019782A1 (fr) Combinaisons d'agents de disruption vasculaire et d'un inhibiteur d'antagonistes des protéines apoptotiques
Bing et al. Indapamide and bendrofluazide: a comparison in the management of essential hypertension.
Imagawa et al. Preferential inhibitory effect of nifedipine on angiotensin II-induced renal vasoconstriction.
Thamaree et al. Changes in renal hemodynamics induced by Russell’s viper venom: effects of indomethacin
VELASQUEZ et al. Effect of probenecid on the natriuresis and renin release induced by bumetanide in man

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20010125